Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Next Previous
Trial Profile

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amivantamab (Primary) ; Amivantamab (Primary) ; Chlorhexidine (Primary) ; Clindamycin (Primary) ; Doxycycline (Primary) ; Lazertinib (Primary) ; Minocycline (Primary) ; Ruxolitinib (Primary) ; Tacrolimus (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms COCOON
  • Sponsors Janssen Research & Development

Most Recent Events

  • 29 Apr 2025 Status changed from active, no longer recruiting to recruiting.
  • 04 Apr 2025 Status changed from recruiting to active, no longer recruiting.
  • 28 Mar 2025 Planned number of patients changed from 200 to 300.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top